7月16日，Definium Therapeutics盘中上涨5.5%，报46.68美元/股，成交额2316.68万美元。
消息面上，公司核心候选药物DT120口崩片治疗重度抑郁症的3期EMERGE研究此前取得积极顶线结果，主要终点及所有关键次要疗效终点均达成。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权。RBC Capital将目标价从36美元大幅上调至57美元，维持"跑赢大盘"评级，当前股价仍低于该目标价。此外，礼来当日宣布以38亿美元溢价收购同属精神疾病赛道的AtaiBeckley，进一步验证了迷幻药精神科领域的投资价值，形成板块联动效应。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.